[186-POS]

Abstracts / Pregnancy Hypertension: An International Journal of Women’s Cardiovascular Health 5 (2015) 53–156

preeclampsia, gestational diabetes, fetal growth disorders) for development of new biomarkers. (2) To translate the discovery findings from retrospective study cohort containing the selected and well-characterized clinical phenotypes into clinical practice using longitudinal sample collection. Methods: REPROMETA (REPROgrammed fetal and/or maternal METAbolism) study individuals (family trios/duos) were recruited at delivery at the Women Clinic of Tartu University Hospital in 2006–2011. The babies were followed-up for two years. In the frame of the ongoing prospective study HAPPY PREGNANCY (‘‘Development of novel non-invasive biomarkers for fertility and healthy pregnancy’’; 2013– 2015) we are collecting longitudinal anthropometric, epidemiological, clinical data and biological material thorough the pregnancy and at delivery. The estimated number of participants is 2500. Results: Retrospective sample collection consists of 366 families: (1) uncomplicated pregnancy resulted with term delivery of baby with normal birth weight (n = 110); (2) babies of large (n = 89); and (3) small for gestational age (n = 64); (4) cases of severe preeclampsia (n = 50); (5) gestational diabetes (n = 53). None of the children had genetic syndrome or late-onset of congenital malfunction at the age of 2 years. The biological material (DNA, RNA, plasma, paraffin blocks) have used in several studies (Männik et al., 2010, 2012; Uusküla et al., 2012). The quality of the samples was featured in an editorial of JCEM (Freemark, 2010). The HAPPY PREGNANCY study is recruiting 2/3 of all pregnant women visiting Women’s Hospital. Preliminary prevalence of preeclampsia is 3.8%, preterm delivery 5.4%, multiple pregnancy 5.4%, gestational diabetes 4.1% in study cohort (www.happypregnancy.ut.ee/eng). Conclusions: We have been creating a powerful biobank enabling development of new biomarkers from discovery to clinical practice. FUNDING: European Regional Development Fund (project 3.2.0701.12-0047). Disclosures: K. Rull: None. P. Vaas: None. E. Hanson: None. P. Teesalu: None. T. Rebane: None. M. Laan: None. doi:10.1016/j.preghy.2014.10.191

[186-POS] Role of coagulation factors in placental abruption in the Chinese population JinYing Yang, Yixin Gao, Yanmin Jiang, Guozheng Zhang, Huishu Liu (Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, China) Objectives: To investigate the clinical significance of TFPI-I and other coagulation factor (FII:C, FV:C, FVII:C, FVIII:C, FIX:C, FX:C, FXI:C, FXII:C) in women with placental abruption. Methods: We used ELISA and clotting assays to examine the changes of TFPI-I and coagulation factors (FII:C, FV:C, FVII:C, FVIII:C, FIX:C, FX:C, FXI:C, FXII:C) in 5 women with

95

placental abruption compared to 5 age-matched, healthy controls with normal vaginal deliveries. Results: The levels of TFPI-1 (18.37 ± 2.61 ng/ml), FV:C (126.63 ± 36.27) and FX:C (117.11 ± 38.75) in placental abruption group were significantly lower than those in the control group (34.63 ± 2.09 ng/ml) (246.41 ± 93.02) (191.73 ± 47.36) (P < 0.05). There were no significant differences for other coagulation factors. Conclusions: Reduced activities of TFPI-1, FV:C, and FX:C in placental abruption may play an important role in the coagulation dysfunction of placental abruption. Disclosures: J. Yang: None. Y. Gao: None. Y. Jiang: None. G. Zhang: None. H. Liu: None. doi:10.1016/j.preghy.2014.10.192

[187-POS] Cyclosporin A attenuate inflammatory response on lowdose endotoxin induced preeclampsia in rat Bihui Hu a, Huishu Liu a, Qian Huang a, JinYing Yang a, Yanmin Jiang a, Junjie Bao a, Shaun Patrick Brennecke b (a Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, China, b Department of Perinatal Medicine Pregnancy Research Centre and University of Melbourne Department of Obstetrics and Gynaecology, Royal Women’s Hospital, Parkville, Victoria, Australia) Objectives: Preeclampsia (PE) is a severe complication of pregnancy characterized by an excessive maternal systemic inflammatory response with activation of the immune system. However, few therapeutic options exist aside from delivery. In treating variety of diseases, CsA exertits positive effects by immunosuppressive role. The aim of the study was to test the hypothesis that Cyclosporin A attenuate inflammatory response on a preeclampsia model. Methods: Using a low dose of lipopolysaccharide (LPS, 1.0 lg/kg) on gestational day (GD) 14 to induced preeclampsia (PE) rat model. CsA was administrated by 5 mg/kg or 10 mg/kg on day of 16, 17, 18 of pregnancy based on the PE model. Then we compared blood pressure,urinary albumin,biometric parameters (ALT, AST, SCr, BUN) and the levels of serum cytokines (IL-2, IL-4, IL-6, IL-10, IL-17, TNF-a, IFN-cÞ before and after we suppressed the inflammatory response by Cyclosporin A (CsA) in two doses. Results: After LPS treatment, the systolic blood pressure (SBP) was significantly higher on GD16 (p < 0.01). CsA 5 mg/kg or 10 mg/kg i.p. infusion significantly decreased SBP on GD19 (p < 0.01). The mean level of 24-h urinary albumin excretion was significantly higher in PE group than NP group on GD19 (p < 0.01). Administration of CsA caused a marked reduction in urinary albumin compared with PE group (p < 0.01).These were significantly increased (p < 0.05) level of serum T helper-1 (Th1)-type inflammatory cytokines IL-6 TNF-a and IFN-c, as well as T helper-17 (Th17)-type inflammatory cytokine IL-17 in the PE group. These levels decreased following CsA administration. The serum T helper-2 (Th2)-type inflammatory cytokine IL-4